Volume 95 Issue 20 | p. 16 | News of The Week
Issue Date: May 15, 2017

Patient dies in Kite drug trial

Incident is another setback for CAR-T cancer immunotherapies
Department: Business
Keywords: oncology, immunotherapy, CAR-T therapy, Kite, Juno

In a development with an uncomfortable parallel, Kite Pharma reported a death in a clinical trial of a cancer immunotherapy based on chimeric antigen receptor T-cell technology, commonly known as CAR-T therapy.

CAR-T therapies are created by removing T cells from a patient, engineering them to hunt a specific kind of cancer cell, growing them in a bioreactor, and then returning them to the patient.

. . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society